Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial.

IF 1.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Pakistan Journal of Medical Sciences Pub Date : 2025-01-01 DOI:10.12669/pjms.41.1.8496

Hina Akram Mudassir, Syed Muhammed Talha Arshad, Munazzah Naheed, Sadia Anwer

{"title":"Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial.","authors":"Hina Akram Mudassir, Syed Muhammed Talha Arshad, Munazzah Naheed, Sadia Anwer","doi":"10.12669/pjms.41.1.8496","DOIUrl":null,"url":null,"abstract":"Objective: To explore the effect of Centratherum antheminticum seeds powder {Cap CASP 500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.Methods: A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into PGroup (Positive Control, metformin 500 mg) & TGroup (Test, Cap CASP + was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). CGroup (healthy control), was also included with twenty healthy volunteers with same dose of Cap CASP. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.Results: CASP showed potent (in-vitro) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of in-vivo parameters in TGroup showed significant improvements. Body weight (p<0.01) & (p<0.05), HbA1c & fasting blood glucose (p<0.0001), coronary risk index (CRI), atherogenic index (A Indx) (p<0.05, p<0.0001) & atherogenic dyslipidemia ratio (A-DLR) (p<0.0001 & p<0.01) were reduced after six and twelve weeks. Reduction in serum cholesterol and triglycerides (p< 0.05 & p< 0.01) after six as well as (p< 0.01) after twelve weeks. Very low density lipoprotein reduced after both (p< 0.05) six and (p< 0.0001) twelve weeks. High density lipoprotein increased (p< 0.01) & low density lipoprotein decreased (p< 0.05) after twelve weeks.Conclusion: When given standard care to T2D patients, the CASP intervention demonstrated both anti-diabetic and anti-lipidemic effects.","PeriodicalId":19958,"journal":{"name":"Pakistan Journal of Medical Sciences","volume":"41 1","pages":"257-262"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755271/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12669/pjms.41.1.8496","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the effect of Centratherum antheminticum seeds powder {Cap _CASP 500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.

Methods: A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P_Group (Positive Control, metformin 500 mg) & T_Group (Test, Cap _CASP + was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). C_Group (healthy control), was also included with twenty healthy volunteers with same dose of Cap _CASP. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.

Results: CASP showed potent (in-vitro) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of in-vivo parameters in T_Group showed significant improvements. Body weight (p<0.01) & (p<0.05), HbA1c & fasting blood glucose (p<0.0001), coronary risk index (CRI), atherogenic index (A Indx) (p<0.05, p<0.0001) & atherogenic dyslipidemia ratio (A-DLR) (p<0.0001 & p<0.01) were reduced after six and twelve weeks. Reduction in serum cholesterol and triglycerides (p< 0.05 & p< 0.01) after six as well as (p< 0.01) after twelve weeks. Very low density lipoprotein reduced after both (p< 0.05) six and (p< 0.0001) twelve weeks. High density lipoprotein increased (p< 0.01) & low density lipoprotein decreased (p< 0.05) after twelve weeks.

Conclusion: When given standard care to T2D patients, the CASP intervention demonstrated both anti-diabetic and anti-lipidemic effects.

查看原文本刊更多论文

目的探讨卡拉奇2型糖尿病（T2DM）患者服用积雪草种子粉{Cap CASP 500 mg}胶囊的效果：2019年10月至12月，在信德省政府医院新卡拉奇分院随机选取了40名T2DM患者，在征得其同意后进行了非盲法对照试验，并将其分为PG组（阳性对照组，二甲双胍500毫克）和TG组（试验组，Cap CASP +），对20名健康志愿者使用相同剂量的CapCASP。数据分析采用在线图形垫学生 t 检验和单因素方差分析（SPSS 24 版），每组二甲双胍 500 毫克。）两组均有（n = 20）。CG组（健康对照组）也包括 20 名健康志愿者，服用相同剂量的 Cap CASP。两组的生化测试（血脂、HbA1c、空腹血糖）均在联邦乌尔都艺术、科学与技术大学生化实验室完成，结果通过单因素方差分析（SPSS 24 版）和在线图形垫学生 t 检验进行分析：与标准阿卡波糖（标准药物）相比，CASP 在体外显示出了强效的抗糖尿病活性（72.81%）。T 组的大多数体内参数都有明显改善。体重（ppppppp< 0.05 和 p<0.01）在六周后有所改善，（p< 0.01）在十二周后也有所改善。极低密度脂蛋白在六周后降低（p< 0.05），十二周后降低（p< 0.0001）。十二周后，高密度脂蛋白升高（p< 0.01），低密度脂蛋白降低（p< 0.05）：结论：在对 T2D 患者进行标准治疗时，CASP 干预疗法同时具有抗糖尿病和降血脂的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pakistan Journal of Medical Sciences 医学-医学：内科

CiteScore

4.10

自引率

9.10%

发文量

363

审稿时长

3-6 weeks

期刊介绍： It is a peer reviewed medical journal published regularly since 1984. It was previously known as quarterly "SPECIALIST" till December 31st 1999. It publishes original research articles, review articles, current practices, short communications & case reports. It attracts manuscripts not only from within Pakistan but also from over fifty countries from abroad. Copies of PJMS are sent to all the import medical libraries all over Pakistan and overseas particularly in South East Asia and Asia Pacific besides WHO EMRO Region countries. Eminent members of the medical profession at home and abroad regularly contribute their write-ups, manuscripts in our publications. We pursue an independent editorial policy, which allows an opportunity to the healthcare professionals to express their views without any fear or favour. That is why many opinion makers among the medical and pharmaceutical profession use this publication to communicate their viewpoint.